ES2902835T3 - Composiciones celulares mejoradas y métodos para la terapia contra el cáncer - Google Patents

Composiciones celulares mejoradas y métodos para la terapia contra el cáncer Download PDF

Info

Publication number
ES2902835T3
ES2902835T3 ES15734922T ES15734922T ES2902835T3 ES 2902835 T3 ES2902835 T3 ES 2902835T3 ES 15734922 T ES15734922 T ES 15734922T ES 15734922 T ES15734922 T ES 15734922T ES 2902835 T3 ES2902835 T3 ES 2902835T3
Authority
ES
Spain
Prior art keywords
ntb
ectodomain
cells
agonist
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15734922T
Other languages
English (en)
Spanish (es)
Inventor
Abraham Rutenberg
Ronny Uzana
Michal Lotem
Arthur Machlenkin
Galit Eisenberg
Tamar Peretz-Yablonsky
Shoshana Frankenburg
Roni Engelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Original Assignee
Hadasit Medical Research Services and Development Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53523593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2902835(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hadasit Medical Research Services and Development Co filed Critical Hadasit Medical Research Services and Development Co
Application granted granted Critical
Publication of ES2902835T3 publication Critical patent/ES2902835T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES15734922T 2014-01-09 2015-01-08 Composiciones celulares mejoradas y métodos para la terapia contra el cáncer Active ES2902835T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925265P 2014-01-09 2014-01-09
PCT/IL2015/050033 WO2015104711A1 (en) 2014-01-09 2015-01-08 Improved cell compositions and methods for cancer therapy

Publications (1)

Publication Number Publication Date
ES2902835T3 true ES2902835T3 (es) 2022-03-30

Family

ID=53523593

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15734922T Active ES2902835T3 (es) 2014-01-09 2015-01-08 Composiciones celulares mejoradas y métodos para la terapia contra el cáncer

Country Status (7)

Country Link
US (3) US10344073B2 (enExample)
EP (2) EP3091999B2 (enExample)
JP (2) JP6682438B2 (enExample)
AU (1) AU2015205327B2 (enExample)
ES (1) ES2902835T3 (enExample)
IL (1) IL246607B (enExample)
WO (1) WO2015104711A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10780080B2 (en) * 2016-11-23 2020-09-22 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
CN107502589A (zh) * 2017-08-04 2017-12-22 北京世纪劲得生物技术有限公司 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法
WO2019126736A1 (en) * 2017-12-21 2019-06-27 New York University Pd-1 related cancer therapy
EP3914267A1 (en) * 2018-01-25 2021-12-01 Mia Levite Methods for improved immunotherapy
JP7458318B2 (ja) * 2018-02-12 2024-03-29 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節
IL267614A (en) * 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
JP7604401B2 (ja) 2019-07-03 2024-12-23 オックスフォード バイオセラピューティックス リミテッド 抗体および使用方法
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US7479269B2 (en) * 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
US6284267B1 (en) 1996-08-14 2001-09-04 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
JP4326944B2 (ja) 2001-07-19 2009-09-09 イネイト・ファーマ ナチュラルキラー細胞活性に関与する表面分子ｎｔｂ−ａ
MXPA04001986A (es) 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP2005206478A (ja) 2004-01-20 2005-08-04 Kirin Brewery Co Ltd 樹状細胞膜分子−ＩｇＦｃ融合ポリペプチドまたはそれに対する抗体を含む医薬組成物
WO2005124346A1 (en) * 2004-05-17 2005-12-29 The Board Of Trustees Of The University Of Illinois 4-1bb receptors are expressed on regulatory t-cells
EP1642905B1 (en) 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
WO2007020880A1 (ja) * 2005-08-17 2007-02-22 Takara Bio Inc. リンパ球の製造方法
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
TW200823237A (en) * 2006-08-28 2008-06-01 Nuvelo Inc Antibodies to NTB-A
WO2009065065A1 (en) 2007-11-15 2009-05-22 Ceramoptec Industries, Inc. Pegylated liposomal formulations for photodynamic treatment of inflammatory diseases
US20120244133A1 (en) * 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms

Also Published As

Publication number Publication date
JP2017503810A (ja) 2017-02-02
US20230078665A1 (en) 2023-03-16
IL246607A0 (en) 2016-08-31
AU2015205327B2 (en) 2019-02-14
EP3091999B1 (en) 2021-10-20
WO2015104711A1 (en) 2015-07-16
IL246607B (en) 2022-02-01
JP6682438B2 (ja) 2020-04-15
US20160333072A1 (en) 2016-11-17
EP3091999A1 (en) 2016-11-16
US20190330303A1 (en) 2019-10-31
AU2015205327A1 (en) 2016-07-21
US10344073B2 (en) 2019-07-09
EP3091999B2 (en) 2025-05-07
JP7004761B2 (ja) 2022-01-21
JP2020105219A (ja) 2020-07-09
EP3091999A4 (en) 2017-05-24
CA2935903A1 (en) 2015-07-16
US11530251B2 (en) 2022-12-20
EP4101461A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
US20230078665A1 (en) Cell compositions and methods for cancer therapy
ES2315008T3 (es) Composiciones que contienen un agente de union a receptor ox-40 o un acido nucleido que codifica el mismo y procedimientos para potenciar la respuesta inmune especifica de antigeno.
JP7352473B2 (ja) がん細胞を標的化するキメラ抗原受容体のための方法および組成物
ES2979220T3 (es) Constructos quiméricos de anticuerpos/receptores de células T y usos de los mismos
US20250186346A1 (en) Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
ES2777940T3 (es) Células efectoras inmunitarias genomanipuladas con un receptor de antígeno químico específico de CS1
CN110573522B (zh) SIRPα-41BBL融合蛋白及其使用方法
JP2019515888A (ja) 細胞免疫療法前の細胞毒性プレコンディショニングの代替
KR20130045824A (ko) 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
US11986538B2 (en) Immunoswitch nanoparticles for reprogrammed T cell responses
CN110536693A (zh) Pd1-41bbl融合蛋白及使用其的方法
CN104284680A (zh) 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
WO2018195386A1 (en) Methods and compositions for treating cancer with ecm-affinity peptides linked to immunotherapeutic antibodies
AU2022201142A1 (en) Vaccine compositions and methods for restoring NKG2D pathway function against cancers
AU2020307688B2 (en) Combination cancer immunotherapy
WO2024060140A1 (zh) EGFRvIII嵌合抗原受体及其用途
WO2019155474A1 (en) Modulation of slamf6 splice variants for cancer therapy
US20240207406A1 (en) Methods and compositions comprising mhc class i peptides
CN115038462A (zh) 用于中枢神经系统病毒感染和肿瘤的基于t细胞的免疫疗法
Petley Assessment of combined vaccination and immune modulation as an anti-tumour therapy
Old et al. Peptide Vaccine Induces Enhanced Tumor
HK40015393A (en) Compositions and methods for treating cancer
HK1153389A (en) Heat shock protein gp96 vaccination and methods of using same